Morphine desensitization and cellular tolerance are distinguished in rat locus coeruleus neurons

Erica S. Levitt and John T. Williams

Vollum Institute, Oregon Health & Science University, Portland, Oregon 97239
Running Title: Separation of desensitization and cellular tolerance

Corresponding author: John T. Williams
Vollum Institute, Oregon Health & Science University
3181 SW Sam Jackson Park Road
Portland, Oregon 97239
503-494-5465
williamj@ohsu.edu

Text pages: 24
Tables: 0
Figures: 6
References: 46
Number of words
   Abstract: 244
   Introduction: 614
   Discussion: 1468

Abbreviations:
Abstract

Mu opioid receptor desensitization is considered an initial step in the development of tolerance. Curiously, the commonly used opioid morphine produces robust tolerance, but minimal acute desensitization. This study was designed to test the hypothesis that desensitization is indeed present in morphine-treated animals and is distinguished from cellular tolerance by time-course of recovery and mechanism. To induce tolerance, rats were treated with continuously-released morphine for one week. Morphine-mediated activation of G protein-coupled inwardly-rectifying potassium conductance was measured using voltage-clamp recordings from locus coeruleus neurons in brain slices from naïve or morphine-treated rats. Cellular tolerance was observed as a decrease in morphine efficacy in slices from morphine-treated rats. This tolerance persisted for at least 6 hours. An additional reduction in morphine-mediated current was observed when slices from morphine-treated rats were continuously maintained in morphine at approximately the circulating plasma concentration. This additional reduction recovered within an hour after removal of morphine from the slice and represents desensitization that developed in the tolerant animal. Recovery from desensitization, but not long-lasting tolerance, was facilitated by protein phosphatase 1 (PP1) activity. Furthermore, desensitization, but not tolerance, was reversed by protein kinase C (PKC) inhibitors, but not an inhibitor of c-Jun N-terminal kinase. Therefore, morphine treatment leads to both long-lasting cellular tolerance and readily-reversible desensitization, which are differentially dependent on PP1 and PKC activity and combine to result in a substantial decrease in morphine effectiveness. This PKC-mediated desensitization may contribute to the previously reported PKC-dependent reversal of behavioral tolerance.
Introduction

Morphine is one of the most commonly used opioids for treatment of acute and chronic pain. Unfortunately, long-term use of morphine results in tolerance requiring dose escalation. The mechanisms underlying opioid tolerance are not well understood, although many have been proposed (Dang and Christie, 2012). Mu opioid receptor (MOR) desensitization is considered an initial step in the development of opioid tolerance. Many opioid agonists, such as [Met]$^5$enkephalin (ME), [D-Ala$^2$, N-Me-Phe$^4$, Gly$^5$-ol]-enkephalin (DAMGO), etorphine, methadone and fentanyl cause robust acute desensitization (Arttamangkul et al., 2008; Bailey et al., 2003; Virk and Williams, 2008). However, morphine is relatively inefficient at producing acute desensitization in live neurons (Alvarez et al., 2002; Arttamangkul et al., 2008; Bailey et al., 2003; Bailey et al., 2009b; Dang and Williams, 2005). Therefore, the role of desensitization in tolerance to morphine has been questioned (Enquist et al., 2011; Finn and Whistler, 2001).

The terms tolerance and desensitization can both be used accurately to describe a loss of receptor function due to prolonged agonist exposure. Multiple mechanisms likely contribute to the loss of receptor function. As a result, cellular tolerance and desensitization may be separable processes. In this study, tolerance and desensitization were examined on the cellular level in locus coeruleus (LC) neurons contained in brain slices from naïve or morphine-treated rats. Cellular tolerance will be defined as a long-lasting decrease in efficacy found in slices from animals that have been treated for a week with morphine, which persists in the absence of morphine. Desensitization will be defined by a process that recovers over a period of about one hour following the removal of morphine. Using these definitions, cellular tolerance has...
been observed previously in neurons from LC (Christie et al., 1987; Connor et al., 1999) and periaqueductal gray (Bagley et al., 2005) taken from morphine-treated animals. More recently, morphine desensitization was identified in LC neurons from morphine-treated animals, which was dependent on ongoing protein kinase C (PKC) activity (Bailey et al., 2009a). However, in that study cellular tolerance was not observed, leaving open the question of the role of PKC in cellular tolerance versus desensitization. Distinguishing these processes will help unravel the relative contributions of cellular tolerance and desensitization to antinociceptive tolerance, especially given the reversal of antinociceptive tolerance by PKC inhibitors that has been reported previously (Bohn et al., 2002; Hull et al., 2010).

This study tests the hypothesis that both desensitization and cellular tolerance are present in morphine-treated animals and that these processes can be distinguished by the time course of recovery and mechanism. Using whole-cell voltage-clamp recordings from LC neurons contained in rat brain slices, cellular tolerance was observed when slices from morphine-treated rats were incubated in morphine-free physiological buffer for at least 2 hours to wash out any circulating morphine. This effect lasted at least 6 hours and therefore represents long-lasting cellular tolerance. An additional reduction in morphine-mediated current was observed in slices from morphine-treated rats that were continuously maintained in morphine. This additional reduction represents desensitization that was induced in vivo and recovered within an hour after removal of morphine from the slice. Recovery from desensitization, but not long-lasting tolerance, was facilitated by protein phosphatase 1 (PP1) activity. Furthermore, desensitization could be reversed by addition of PKC inhibitors, but not an
inhibitor of c-Jun N-terminal kinase (JNK). Therefore, morphine treatment leads to both long-lasting cellular tolerance and desensitization, which are differentially dependent on PP1 and PKC activity and combine to result in a substantial decrease in morphine effectiveness. The rapid reversal of desensitization, but not cellular tolerance, by PKC inhibitors combined with the reversal of antinociceptive tolerance by PKC inhibitors reported previously (Bohn et al., 2002; Hull et al., 2010) suggests that desensitization contributes to behavioral tolerance.
Materials and Methods

Drugs - Morphine sulfate, morphine alkaloid and cocaine were obtained from the National Institute on Drug Abuse (NIDA), Neuroscience Center (Bethesda, MD). Naloxone, MK801 and SP600125 were from Ascent Scientific (Princeton, NJ). UK14304 tartrate and Go6976 were from Tocris (Ellisville, MO). Potassium methanesulfonate was from Alfa Aesar (Ward Hill, MA). Okadaic acid and calyculin A were from LC Laboratories (Woburn, MA). Staurosporine aglycone, [Met]5enkephalin (ME), bestatin and idazoxan were from Sigma.

Morphine, naloxone, UK14304 tartrate and idazoxan were dissolved in water, diluted in artificial cerebrospinal fluid (ACSF) and applied by bath superfusion. Phosphatase inhibitors, okadaic acid and calyculin A, and kinase inhibitors, Go6976 and staurosporine, were dissolved in DMSO (final concentration < 0.01%) and applied during incubation and superfusion. SP600125 was dissolved in DMSO (final concentration 0.1%). Bath perfusion of ME was with bestatin (10 µM) and thiorphan (1 µM) to limit breakdown of ME.

Animal treatment protocols – All animal experiments were conducted in accordance with the National Institutes of Health guidelines and with approval from the Institutional Animal Care and Use Committee of the Oregon Health & Science University (Portland, OR). Adult (180 – 300 g) male Sprague-Dawley rats (Charles River Laboratories; Wilmington, MA) were used for all experiments. Rats were treated with morphine sulfate continuously released from osmotic pumps as described previously (Quillinan et al., 2011). Osmotic pumps (Alzet 2ML1) were filled with the required concentration of morphine sulfate in water to deliver 50 mg/kg/day. Each pump has a 2 ml reservoir that
releases 10 μl/h for up to 7 days. Rats were anesthetized with isoflurane and an incision was made in the mid-scapular region for subcutaneous implantation of osmotic pumps. Pumps remained until animals were used for experiments 6 or 7 days later.

Tissue preparation – Horizontal slices containing locus coeruleus (LC) neurons were prepared as described previously (Williams and North, 1984). Briefly, rats were killed and the brain was removed, blocked and mounted in a vibratome chamber (Leica VT 1200S). Horizontal slices (230 – 240 μm) were prepared in ice-cold cutting solution containing (in mM): 75 NaCl, 50 sucrose, 2.5 KCl, 6 MgCl2, 0.1 CaCl2, 1.2 NaH2PO4, 2.5 D-glucose, 25 NaHCO3 and 0.01 MK801 (equilibrated with 95% O2/ 5% CO2). Slices were stored at 34°C in glass vials with oxygenated (95% O2/ 5% CO2) artificial cerebrospinal fluid (ACSF) containing (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.6 CaCl2, 1.2 NaH2PO4, 11 D-glucose and 21.4 NaHCO3. In some experiments, morphine (1 μM) was included in the cutting solution and ACSF.

Recordings – After an incubation period of at least 30 min, slices were hemisected and transferred to the recording chamber which was superfused with 34°C ACSF at a rate of 1.5 - 2 ml/min. Whole-cell recordings were made from LC neurons with an Axopatch 1D amplifier in voltage-clamp mode (Vhold = -60 mV). Recording pipettes (1.7 – 2.1 MΩ) were filled with internal solution containing (in mM): 115 potassium methanesulfonate or potassium methyl sulfate, 20 KCl, 1.5 MgCl2, 5 HEPES(K), 10 BAPTA, 2 Mg-ATP, 0.2 Na-GTP, pH 7.4, 275-280 mOsM. Series resistance was monitored without compensation and remained < 15 MΩ for inclusion. Data were collected at 400 Hz with PowerLab (Chart version 5.4.2; AD Instruments, Colorado Springs, CO). Most drugs were applied by bath superfusion. In some experiments, ME was applied by
MOL #81547

iontophoresis with 7 – 15 nA positive current for 2 – 3 seconds from thin-walled glass pipettes (50 - 70 MΩ resistance) filled with 10 mM ME. A backing current of -2 nA was applied to prevent passive leakage.

Data Analysis – Analysis was performed using GraphPad Prism 4 software (La Jolla, CA). Summary data were presented as the morphine-induced current (I – morphine) as a percentage of the UK-mediated current, unless otherwise indicated. Values are presented as mean ± SEM. Statistical comparisons were made using one-way or two-way ANOVA, as appropriate, with Bonferroni’s post-hoc tests. Comparisons with p < 0.05 were considered significant.
Results

Long-lasting cellular tolerance to morphine

Morphine responses were assessed by whole-cell voltage-clamp recordings from locus coeruleus (LC) neurons contained in acute brain slices from opioid naïve or morphine-treated rats. The morphine concentration-response relationship was determined by measuring the outward current produced by various concentrations of morphine. Only one concentration of morphine was tested per slice. Since mu opioid receptors (MOR) and α2-adrenergic receptors activate the same G protein-coupled inwardly rectifying potassium (GIRK) channels (North and Williams, 1985), morphine current was normalized to the current induced by a saturating concentration of the α2-adrenergic agonist UK 14304 (3 μM). In neurons from naïve rats, saturating concentrations of morphine caused an outward current that was 76 ± 3 % of the current produced by UK 14304. The EC50 of morphine was 171 nM (95% confidence interval (CI): 92 -317 nM) (Figure 1 A, D).

To induce tolerance, rats were implanted with osmotic pumps that continuously released morphine (50 mg/kg/day). After 6 or 7 days, slices were prepared from treated animals and incubated in morphine-free ACSF for at least 2 hours to remove any residual morphine. In washed slices from morphine-treated animals (MTA, wash), morphine efficacy was reduced with a decrease in the maximum morphine-mediated current to 53 ± 5 % of UK 14304 (p < 0.01 compared to naïve by two-way ANOVA and Bonferroni’s post-test) (Figure 1 B, D). This decrease in efficacy was not accompanied by a shift in the EC50 (154 nM [95% CI: 22 – 1091 nM]), which indicates a lack of spare receptors and is consistent with previous findings (Christie et al., 1987). Slices were
washed for at least 2 hours, but could be washed for up to 6 hours without affecting the morphine (1 μM)-mediated current, as indicated by the shallow slope of linear regression when the current data were plotted versus wash time (Figure 1E top; slope of linear regression = 1.5 ± 1.8 % of UK/ h, p = 0.41). Therefore, the decrease in morphine effectiveness in slices from morphine-treated animals represents long-lasting tolerance which persists for at least 6 hours after removal of morphine. This long-lasting cellular tolerance was not observed by Bailey et al. (2009a) likely due to a shorter morphine treatment time (3 days vs 6-7 days).

Morphine desensitization also develops in vivo

Previous studies recording from LC neurons in slices from morphine-treated rats have identified a reversible decrease in morphine efficacy that represents desensitization (Bailey et al., 2009a). The next experiments were designed to test the hypothesis that during long-term morphine treatment both desensitization and cellular tolerance are induced. During treatment of rats with morphine (50 mg/kg/day) released from osmotic pumps, neurons are continuously exposed to morphine with a circulating concentration of approximately 1 μM (Quillinan et al., 2011). To maintain the morphine equilibrium, slices from morphine-treated rats were prepared and incubated in ACSF containing morphine (1 μM). Recordings were initiated in the presence of morphine and the morphine-mediated current was revealed upon application of the opioid antagonist naloxone (1 μM; Figure 1C). This morphine-mediated current was much smaller than the current produced by the same concentration of morphine (1 μM) in washed slices.
from morphine-treated rats or in slices from naïve rats (MTA, morphine = 30.1 ± 1.9 % of UK; MTA, wash = 45.0 ± 2.2 % of UK; Naïve = 61.6 ± 1.5 % of UK; summarized in Figure 1D). The morphine desensitization remained consistent regardless of the amount of time the slices were incubated in morphine (1 μM) (Figure 1E bottom, slope of linear regression = 0.8 ± 1.4 % of UK/ h, p = 0.58), indicating that this concentration of morphine effectively mimics the in vivo situation and does not lead to further desensitization. Therefore, the continuous presence of morphine in vivo induces both desensitization and long-lasting tolerance which combine to result in a significant reduction of morphine effectiveness.

To determine the concentration dependence of the desensitization that developed in vivo, slices from morphine-treated rats were incubated in morphine (100 nM) for at least 1.5 hours. This concentration of morphine activates only a small percentage of MOR in slices from naïve or morphine-treated animals (Figure 1D). Recordings were initiated in the presence of morphine (100 nM). Perfusion of morphine (1 μM) resulted in an additional increase in the outward current, and naloxone reversed the morphine (1 μM)-mediated current to baseline. The current induced by morphine (1 μM) in these slices was similar to the current in washed slices (Figure 1D). Therefore, morphine (100 nM) was not sufficient to prevent recovery from desensitization. Furthermore, there was no time-dependence to morphine (100 nM) incubation from 1.5 to 5 hours (slope of linear regression = 0.5 ± 1.9 % of UK/ h, p = 0.78), indicating that desensitization recovered to its full extent within 1.5 hours.

Morphine desensitization was homologous
The decrease in morphine effectiveness could be due to effects on MOR (homologous) or downstream signaling components that are shared by multiple receptors (heterologous). Heterologous desensitization of $\alpha_2$-adrenergic receptor-mediated currents in LC neurons was recently shown to develop after prolonged (>10 min) application of ME (Dang et al., 2012). Therefore, currents mediated by $\alpha_2$-adrenergic receptors were used to examine the presence of heterologous desensitization in slices from morphine-treated rats. The current induced by a saturating concentration of the $\alpha_2$-adrenergic agonist UK 14304 (3 $\mu$M) was similar in slices from naïve rats and slices from morphine-treated rats that were left in morphine or washed (Naïve = 247 ± 15 pA; MTA, wash = 279 ± 19 pA; MTA, morphine = 234 ± 12 pA; p > 0.05 for all comparisons by one-way ANOVA and Bonferroni’s post-test; n = 26-64). Since the UK-mediated current was unchanged, it is a reliable method for normalization of other currents for comparisons between cells. However, at saturating concentration it is not a sensitive measure of heterologous desensitization. To test for heterologous desensitization, a sub-saturating concentration of noradrenaline (NA, 3 $\mu$M) was used. Noradrenaline was perfused with cocaine (3 $\mu$M) to prevent uptake and prazosin (100 nM) to block $\alpha_1$-adrenergic receptors. The current induced by morphine (1 $\mu$M), noradrenaline (3 $\mu$M) and UK 14304 (3 $\mu$M) was measured in slices from naïve rats or in slices from morphine-treated rats that were maintained in morphine (Figure 2). In slices from naïve animals, noradrenaline (3 $\mu$M) produced a current that was 64 ± 4 % of the UK-mediated current. This was not different from the noradrenaline-mediated current in slices from morphine-treated animals (56 ± 4 % of UK, p > 0.05 by unpaired t-test, Figure 2B), indicating a lack of heterologous desensitization between these receptors.
In slices from naïve animals, the noradrenaline-mediated current was 85 ± 7 % of the morphine-mediated current (Figure 2C). If desensitization was mostly heterologous, the morphine- and noradrenaline-mediated currents would be expected to decline similarly and the ratio between the two should remain constant. Instead, the ratio was increased in slices from morphine-treated animals, and noradrenaline produced a current that was 118 ± 13 % of the morphine-mediated current (p = 0.03 by unpaired t-test). Therefore, the desensitization induced by long-term morphine treatment was largely homologous.

Recovery from morphine desensitization

Recovery from ME-induced desensitization occurs in less than one hour (Quillinan et al., 2011). The time-course of recovery from morphine desensitization was determined by washing slices from morphine-treated rats in morphine-free ACSF for various times (15 – 90 min) before initiating recordings. Subsequent perfusion of morphine (1 μM) produced an outward current that was normalized to the current produced by UK 14304 (3 μM). The effect of morphine began to recover after 20 min and completely recovered by 70 min (Figure 3A). The half-time of recovery was 44 ± 7 minutes.

PP1 inhibition slows recovery from morphine desensitization

Dephosphorylation has been proposed to allow resensitization of GPCRs, including MOR after ME-induced desensitization (Dang et al., 2011; Osborne and Williams, 1995). However, phosphorylation of MOR follows a different pattern.
depending on the agonist used with morphine producing weaker phosphorylation in general (Doll et al., 2011; Lau et al., 2011). Two Ser/Thr phosphatase inhibitors were used to determine the role of dephosphorylation in recovery from morphine desensitization. Each phosphatase inhibitor was included in morphine-free ACSF wash for 20 – 90 min. The phosphatase inhibitor okadaic acid (100 nM) did not change the time-course of recovery (Figure 3B; two-way ANOVA [F(1, 54) = 0.94, p = 0.34]). In contrast, the phosphatase inhibitor calyculin A (30 nM) significantly delayed the time-course of recovery (Figure 3C; two-way ANOVA [F(1, 39) = 5.8, p = 0.02]). In slices that were washed with calyculin A, desensitization did not even begin to recover until 60 min of wash (compared to 20 min in control) and the half-time of recovery was 66 ± 3 min. Okadaic acid and calyculin A both inhibit protein phosphatase 2A (PP2A). However, calyculin A is a more potent inhibitor of protein phosphatase 1 (PP1), which has recently been shown to be required for dephosphorylation of MOR (Doll et al., 2012).

Although calyculin A delayed the onset of recovery, desensitization was still able to recover completely by 90 min. The steepness of the recovery curve was not due to breakdown of calyculin A. Slices that were washed in calyculin A that was refreshed every 40 min still recovered completely by 90 min (56 % of UK; n = 2). In okadaic acid and calyculin A, the morphine-mediated current never reached the level of a slice from a naïve animal. Thus, dephosphorylation cannot account for the cellular tolerance observed in slices from morphine-treated animals that were washed in morphine-free ACSF.

At the concentrations used in these experiments, neither okadaic acid nor calyculin A pre-incubation alone changed morphine- or UK- mediated currents in slices
from naïve rats. The current produced by morphine (300 nM) was similar between control slices and slices incubated in okadaic acid (100 nM) for 1 – 4 hours (control = 89 ± 20 pA, okadaic acid = 90 ± 9 pA; n = 8; p = 0.94 by unpaired t-test). The current produced by morphine (1 μM) was also similar between control slices and slices incubated in calyculin A (30 nM) for 0.5 – 2 hours (control = 118 ± 11 pA, calyculin A = 138 ± 19 pA; n = 8 – 18; p = 0.35 by unpaired t-test). The UK 14304 (3 μM)-mediated current was unchanged by pre-incubation with okadaic acid or calyculin A (control = 218 ± 9 pA, okadaic acid = 221 ± 13 pA, calyculin A = 224 ± 15 pA; n = 37–79; p > 0.05 for all comparisons by one-way ANOVA and Bonferroni’s post-test). Together, the lack of effect on current amplitude suggests there are no changes in basal MOR, α₂-adrenergic receptor or GIRK function due to the phosphatase inhibitors at these concentrations. At higher concentrations, both okadaic acid (1 μM) and calyculin A (100 nM) significantly reduced the current induced by UK 14304 (3 μM) (control = 218 ± 9 pA (n = 79), okadaic acid = 175 ± 11 pA (n = 28; p < 0.05), calyculin A = 61 ± 10 pA (n = 3; p < 0.05). Therefore, these higher concentrations were not used in any other experiments.

Morphine washes out of slices in 20 min

Morphine does not quickly wash out of acute slice preparations, which could contribute to the time-course of recovery from desensitization. The washout of morphine was tested in slices from naïve rats by combining bath perfusion of morphine (1 μM) with iontophoresis of ME (Figure 4). Bath perfusion of morphine increased the holding current (Figure 4A, B) and simultaneously decreased the current induced by iontophoresis of ME (Figure 4A, C) due to competition for MOR. Morphine reduced both
the amplitude and the duration of the ME-induced current (Figure 4A, inset). When perfusion was switched to a morphine-free solution, the holding current gradually returned to baseline. By 20 min, the current induced by iontophoresis of ME had also recovered but to a new baseline, which may indicate some desensitization, since the ME-induced current in the absence of morphine did not decline (Figure 4C). Perfusion of the opioid antagonist naloxone (1 μM) at the end of these experiments abolished the ME-induced current to 3 ± 1 % of baseline (n = 7) but did not change the holding current, suggesting that there was no residual morphine in the slice.

These data indicate that morphine (1 μM) washes out of slices in 20 minutes. By comparison, at 20 minutes the recovery from morphine desensitization described previously (Figure 3) had only just begun. Together, these results suggest that the time-course of recovery from morphine desensitization measured in slices occurs in a step-wise process. First, the concentration of morphine in the slice is reduced during washout to a level that is insufficient to maintain desensitization (< 100 nM). Then, MOR is resensitized in a PP1-facilitated manner.

Recovery from acute ME-induced desensitization

Morphine- and ME-induced desensitization may occur through different kinase-dependent mechanisms in LC neurons (Bailey et al., 2009b). The effect of calyculin A on recovery from ME-induced desensitization was tested in slices from naïve rats using a protocol described previously (Quillinan et al., 2011). Briefly, an EC50 concentration of ME (300 nM) was tested just prior to prolonged (10 min) application of a saturating concentration of ME (30 μM). The EC50 concentration of ME was then perfused every
10 min to monitor recovery from desensitization (Figure 5A). Control experiments were compared to experiments in which slices were incubated in calyculin A (30 nM) for 30-60 min before the recording. Calyculin A was also included in wash and ME (30 μM) perfusions. Calyculin A did not change the decline in peak current observed during 10 min application of saturating ME (control = 40 ± 2 % decline, calyculin A = 38 ± 3 % decline; n = 10; p = 0.73 by unpaired t-test). Calyculin A did, however, slow the recovery from desensitization (Figure 5B; two-way ANOVA [F(2,46) = 7.08, p = 0.002]). Although this effect was qualitatively smaller than the effect of calyculin A on recovery from morphine desensitization, it indicates that recovery from morphine- and ME-induced desensitization share mechanistic components.

PKC, but not JNK, inhibitors reverse desensitization

Since desensitization and cellular tolerance can be separated by time-course of recovery, differences in mechanism can be further examined. Morphine desensitization in LC neurons has been shown to be dependent on ongoing PKC activity (Bailey et al., 2009a). However, it is unclear whether long-lasting cellular tolerance has a similar requirement. Since both cellular tolerance and desensitization were observed in this study, the role of PKC in these two processes could be assessed. Slices from morphine-treated rats were maintained in morphine and a PKC inhibitor, Go6976 (1 μM) or staurosporine (1 μM), was added with morphine for 30 - 90 minutes. Recordings were initiated in the presence of morphine and PKC inhibitor, and the morphine-mediated current was revealed upon application of naloxone. When slices were incubated with
either Go6976 or staurosporine, morphine desensitization was no longer observed (Figure 6A; MTA, morphine + Go or Sts), consistent with previous findings (Bailey et al., 2009a). The morphine-mediated current after either PKC inhibitor was similar to washed slices from morphine-treated animals (p > 0.05 vs MTA, wash), but still smaller than slices from naïve rats (Go, p < 0.05 vs Naïve/Ctrl; Sts, p < 0.01 vs Naïve/Ctrl). These results suggest that the PKC inhibitors did not reverse long-lasting cellular tolerance. To directly test the role of PKC in cellular tolerance, Go6976 (1 μM) was added to washed slices from morphine-treated rats. Go6976 was either added during the entire wash (2 – 4.5 h) or was added for 1 – 2 hours after an initial wash (> 2 h). Similar results were obtained with both protocols, so the data were pooled. Go6976 did not change the degree of long-lasting cellular tolerance observed in washed slices from morphine-treated rats (Figure 6; p > 0.05 vs MTA, wash/Ctrl) and the morphine-mediated current remained smaller than in slices from naïve rats (p < 0.01 vs Naïve/Ctrl). This lack of effect of Go6976 on long-lasting tolerance persisted even after prolonged incubation times of up to 4.5 hours. Therefore, PKC inhibitors were able to reverse morphine desensitization, but not long-lasting cellular tolerance.

Activity of c-Jun N-terminal kinase (JNK) has been implicated in morphine tolerance (Melief et al., 2010). The role of JNK in morphine desensitization and cellular tolerance in LC neurons was examined using a protocol similar to PKC inhibitor experiments. The JNK inhibitor SP600125 (10 μM) was added for 30 – 120 minutes with morphine to slices from morphine-treated animals. In contrast to PKC inhibitors, incubation with the JNK inhibitor was unable to reverse morphine desensitization (Figure 6A; p > 0.05 vs MTA, morphine). The JNK inhibitor was also unable to reverse
long-lasting cellular tolerance when added during the entire morphine-free wash (2 - 3.5 h) of slices from morphine-treated rats (p < 0.01 vs Naïve/Ctrl).

To address the possibility that JNK is involved in the development, rather than the maintenance, of desensitization, slices from naïve animals were incubated in morphine (1 μM) with or without the JNK inhibitor SP600125 for several hours. Morphine (1 μM) incubation did result in some desensitization in control slices as indicated by the negative slope of linear regression (Figure 6B; slope = -3.5 ± 0.8 % of UK/ h, significantly non-zero p < 0.0001). The desensitization developed slowly and did not reach significance until more than 5 hours of incubation with morphine (p < 0.01 at 5 hours compared to no morphine incubation, one-way ANOVA and Bonferroni's post-test). After 5 – 6 hours in morphine, the morphine-mediated current was 37.8 ± 2.7 % of the current induced by UK 14304. This was desensitized compared to slices incubated in morphine-free ACSF for 4 – 6 hours (52.1 ± 5.7 % of UK; n = 6; p < 0.05 unpaired t-test). Slices incubated in morphine and JNK inhibitor SP600125 desensitized with a similar slope of linear regression as control slices (slope = -3.8 ± 1.1 % of UK/ h, significantly non-zero p = 0.002). Thus, there was no effect of JNK inhibitor on the development of desensitization in slices from naïve rats (two-way ANOVA [F(1,41) = 2.1, p = 0.15]).

None of the kinase inhibitors altered the morphine-mediated current in slices from naïve animals (Figure 6A; p > 0.05 compared to naïve in the absence of inhibitor). The amplitude of the UK-mediated current was also unchanged by the kinase inhibitors (Control = 250 ± 15 pA; Go6976 = 215 ± 11 pA; staurosporine = 257 ± 23 pA; SP600125 = 227 ± 21 pA; p > 0.05 for all inhibitors compared to control by one-way
ANOVA and Bonferroni's post-test). Together, these results indicate that ongoing PKC, but not JNK, activity is essential for morphine desensitization. Furthermore, cellular tolerance cannot be readily reversed by either PKC or JNK inhibitors.
Discussion

Although morphine causes significant behavioral tolerance, it has been thought to cause comparatively little desensitization, raising doubts about the link between desensitization and tolerance. This study distinguished desensitization and cellular tolerance as separate processes, which is necessary to determine the relative role of these processes in behavioral tolerance and identify the mechanisms regulating both. Long-term treatment of rats with continuously-released morphine caused desensitization, consistent with previous findings (Bailey et al., 2009a). In addition, morphine-treated animals developed long-lasting cellular tolerance which did not recover even 6 hours after removal of morphine. Desensitization required the continuous presence of morphine and ongoing PKC activity, and recovered in a PP1-facilitated manner. Unlike desensitization, long-lasting cellular tolerance was not affected by phosphatase or kinase inhibition. Therefore, long-term morphine treatment causes both long-lasting cellular tolerance and desensitization that combine to result in a significant decrease in morphine effectiveness. Previously, antinociceptive tolerance has been shown to be reversed by PKC inhibitors (Hull et al., 2010). Given that PKC inhibition would only reverse desensitization in this amount of time (not cellular tolerance), the PKC inhibitor-mediated reversal of behavioral tolerance can be attributed to reversal of desensitization. Thus, desensitization does contribute to behavioral tolerance.

Morphine desensitization and efficacy

Morphine causes very little acute desensitization in neurons when applied for relatively short times (Alvarez et al., 2002; Arttamangkul et al., 2008; Bailey et al., 2003;
Dang and Williams, 2005). However, in this study, morphine induced desensitization during continuous exposure either for several hours in slices from naïve rats or for several days in morphine-treated rats. This is consistent with findings that a saturating concentration of morphine produces a similar degree of functional receptor loss (80%) as DAMGO after 8 hours (Bailey et al., 2009a). DAMGO or ME can induce this high level of receptor loss (90%) in just 5 - 10 minutes (Bailey et al., 2009a; Osborne and Williams, 1995). Lower concentrations of DAMGO or ME take longer to reach a similar degree of receptor loss and produce little to no desensitization in 5 – 10 minutes (Bailey et al., 2009a; Fiorillo and Williams, 1996; Virk and Williams, 2008). Therefore, differences in desensitization induced by morphine and highly efficacious agonists, such as ME or DAMGO, may be rate-dependent due to differences in efficacy. Indeed, relative agonist efficacy and degree of desensitization are often positively correlated, though some exceptions exist (Borgland et al., 2003; Virk and Williams, 2008).

Phosphorylation and recovery from desensitization

Given the vast difference in the time required to induce desensitization by morphine and ME (hours/days vs minutes), the recovery from desensitization for these two agonists were surprisingly similar. Both morphine- and ME-induced desensitization recovered in less than one hour after the removal of agonist. Dephosphorylation is thought to allow resensitization of GPCRs, including MOR (Dang et al., 2011; Osborne and Williams, 1995). Dephosphorylation of MOR (at S375) expressed in HEK293 cells occurs slightly faster than the recovery from desensitization presented here, but is similar for both morphine- and DAMGO-induced phosphorylation (Doll et al., 2011).
the present study, the Ser/Thr phosphatase inhibitor calyculin A, but not okadaic acid, delayed recovery from morphine-induced desensitization. Calyculin A, but not okadaic acid, has been shown to prevent dephosphorylation of MOR, which was due to activity of PP1 (Doll et al., 2012). Recovery from acute ME-induced desensitization was also slowed by calyculin A. In a previous study, recovery from ME-induced desensitization was not changed by okadaic acid, but was delayed by microcystin (Osborne and Williams, 1995). Similar to calyculin A, microcystin inhibits both PP1 and PP2A equally (MacKintosh et al., 1990). Thus, morphine and ME both induced desensitization that recovered in one hour and was facilitated by PP1. These similarities suggest that even though morphine and ME induce different trafficking patterns (Arttamangkul et al., 2008), resensitization occurs through a common process regardless of the agonist used to induce desensitization.

Kinases in morphine desensitization

Previously, morphine desensitization in LC neurons from morphine-tolerant rats has been shown to be dependent on ongoing PKC activity that was mostly attributed to PKC\(\alpha\) (Bailey et al., 2009a). These results have been replicated here using two PKC inhibitors with slightly different selectivity patterns. Staurosporine is notoriously broad spectrum. The main overlapping enzymes, besides PKC, inhibited by both Go6976 and staurosporine are 3-phosphoinositide-dependent protein kinase 1 (PDK1), phosphorylase kinase (PHK) and checkpoint kinase 1 (CHK1) (Davies et al., 2000; Karaman et al., 2008). The JNK inhibitor SP600125 also inhibits PHK and CHK1 to a significant degree and slightly inhibits PDK1 (Bain et al., 2003). Since SP600125 did not
affect morphine desensitization, these three enzymes are likely not involved in the effect of staurosporine and Go6976. Therefore, PKC is the most likely enzyme responsible for the effect of staurosporine and Go6976.

The site of action of PKC cannot be determined from these studies, but a possible site is phosphorylation of MOR itself. MOR is phosphorylated at multiple Ser/Thr residues on the C-terminal tail, both constitutively and in response to agonist (Doll et al., 2011; El Kouhen et al., 2001; Lau et al., 2011; Wang et al., 2002). PKC can phosphorylate S363 and T370, but neither of these sites is phosphorylated in response to morphine (Doll et al., 2011; Feng et al., 2011). In fact, bulk phosphorylation of MOR induced by morphine was not blocked by staurosporine (Zhang et al., 1996). Rather, morphine desensitization may require multiple phosphorylation sites including those phosphorylated by constitutive PKC activity (ie. T370) and those phosphorylated in response to morphine (ie. S375) (Doll et al., 2011). DAMGO, which does not require PKC for desensitization (Bailey et al., 2009b), effectively phosphorylates both T370 and S375 (Doll et al., 2011).

Recently, PKC has been shown to cause heterologous desensitization in HEK293 cells by phosphorylation of Gαi2 (Chu et al., 2010). Heterologous desensitization between MOR and α2-adrenergic receptors was not observed here or in previous studies using LC neurons (Bailey et al., 2009a; Dang and Williams, 2004). Thus, prolonged morphine treatment did not alter the signaling proteins shared with α2-adrenergic receptors. However, heterologous desensitization of other GPCRs cannot be ruled out.
JNK was recently shown to be required for morphine tolerance in a ligand-specific manner (Melief et al., 2010). The role of JNK in morphine desensitization was previously untested. Unlike PKC inhibitors, addition of the JNK inhibitor SP600125 to slices from morphine-treated animals was unable to reverse morphine desensitization. Furthermore, the JNK inhibitor did not alter the development of desensitization in slices that were incubated in morphine for several hours. Therefore, JNK does not appear to be involved in the maintenance or development of morphine desensitization in LC neurons. The process reported by Melief et al. (2010) is more representative of cellular tolerance (as defined here) since morphine was washed away before cellular assays were performed. Thus, cellular tolerance rather than desensitization may be the mechanism by which JNK regulates morphine tolerance. Alternatively, regulation of desensitization can be different depending on the cell or synaptic context (Blanchet and Luscher, 2002; Fyfe et al., 2010; Pennock et al., 2012). JNK has been shown to mediate desensitization of voltage-gated calcium channels in dorsal root ganglia neurons (Mittal et al., 2012).

Cellular tolerance

None of the manipulations performed in this study (PKC, JNK or phosphatase inhibitors) could reverse cellular tolerance. Since JNK inhibition and knock-down has been shown to prevent the development of cellular tolerance (Melief et al., 2010), the negative result presented here likely represents that cellular tolerance is a long-lasting consequence resulting from adaptive changes that are not readily reversible. There are other manipulations that prevent the development of cellular tolerance, most notably the
loss of β-arrestin 2 (Bohn et al., 2000; Dang et al., 2011). However, β-arrestin 2 is not required for acute ME-induced desensitization (Dang et al., 2011; Quillinan et al., 2011). Instead, β-arrestin 2 may link desensitization and tolerance by slowing recovery from desensitization. Long-term treatment of animals with morphine produces β-arrestin 2- and GRK2-dependent adaptive changes that reduce receptor recycling and reduce recovery from ME-induced desensitization (Dang et al., 2011; Quillinan et al., 2011).

Desensitization can contribute to behavioral tolerance

The morphine desensitization described in this study required the continuous presence of a significant concentration of morphine and recovered in less than one hour in the absence of morphine. This rapid recovery from desensitization could contribute to differences observed in the tolerance produced by intermittent versus continuous administration of morphine. In slices from rats that were treated intermittently with morphine, cellular tolerance in periaqueductal gray neurons was not only lost, but ME was actually more potent at inducing GIRK current (Ingram et al., 2008). Furthermore, intermittent morphine treatment causes less antinociceptive tolerance than continuous treatment (Dighe et al., 2009). Often, desensitization and tolerance are considered interchangeable. This study argues that careful investigation of desensitization as a process separate from cellular tolerance is critical to understanding the decrease in MOR function during long-term opioid exposure.
Acknowledgments

We thank Drs. Seksiri Arttamangkul and William Birdsong for comments on the manuscript.

Authorship Contributions

Participated in research design: Levitt and Williams
Conducted experiments: Levitt and Williams
Performed data analysis: Levitt
Wrote or contributed to writing of the manuscript: Levitt and Williams
MOL #81547

References


Wang HL, Chang WT, Hsu CY, Huang PC, Chow YW and Li AH (2002) Identification of two C-terminal amino acids, Ser(355) and Thr(357), required for short-term


Footnotes

This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants R01-DA08163 and F32-DA33036] and National Institute of Neurological Disorders and Stroke [Grant T32-NS07381].

Parts of this work were previously presented at the International Narcotics Research Conference, June 21-25, 2011, Hollywood, FL, and the Winter Conference on Brain Research, January 21-26, 2012, Snowbird, UT.

Reprint requests to: Dr. John Williams, Vollum Institute, L474, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239. E-mail: williamj@ohsu.edu.
Figure legends

Figure 1. Morphine tolerance and desensitization induced in vivo.

A, B and C, Examples of whole-cell voltage-clamp recordings from LC neurons in slices from opioid-naïve rats (A) or slices from morphine-treated rats (MTA) that were washed for at least 2 h (B) or maintained in morphine (1 μM) (C). The outward potassium current induced by morphine (1 μM) was reversed by opioid antagonist naloxone (1 μM) and normalized to the current produced by the α2-adrenergic receptor agonist UK 14304 (3 μM), which was reversed by α2-adrenergic antagonist idazoxan (1 μM). Data are presented as the morphine-induced current (I – morphine) as a percentage of the UK-mediated current. D, Concentration-response curves for morphine in slices from opioid-naïve rats (Naïve) or washed slices from morphine-treated rats (MTA, wash) reveals long-lasting tolerance (two-way ANOVA: treatment [F(1, 66) = 26.7, p < 0.0001], n = 3 – 15). In addition, the current produced by morphine (1 μM) was significantly desensitized in slices from morphine-treated rats that were maintained in morphine (1 μM) (MTA, morphine 1 μM) (p < 0.001 vs MTA, wash by one-way ANOVA and Bonferroni’s post-test; n = 32). In contrast, the morphine (1 μM) current was not desensitized in slices from morphine-treated rats that were incubated in morphine (100 nM) (MTA, morphine 100 nM), but instead was similar to the current in washed slices (p > 0.05 vs MTA, wash by one-way ANOVA and Bonferroni’s post-test; n = 14). E, Effect of wash or morphine (1 μM) incubation time. Each data point represents a single experiment. Top, slices from morphine-treated rats were washed for 1 - 6 hours before recording the current produced by morphine (1 μM). Slope of linear regression is not different from zero, indicating no effect of long wash times (slope = 1.5 ± 1.8 % of UK/ h, p = 0.41). Bottom,
slices from morphine-treated rats were incubated in morphine (1 μM) for several hours. Recordings were initiated in morphine (1 μM) and reversed with naloxone (1 μM) to reveal the morphine-mediated current. The slope of linear regression is not different from zero, suggesting no effect of longer morphine (1 μM) incubation times (slope = 0.8 ± 1.4 % of UK/ h, p = 0.58).

Figure 2. Lack of heterologous desensitization.

The current mediated by a sub-saturating concentration of noradrenaline (NA, 3 μM) was measured in slices from naïve rats, or slices from morphine-treated rats that were maintained in morphine (1 μM; MTA morphine). A, Example whole-cell voltage-clamp recording in a slice from a naïve rat. Holding current changes were monitored following bath perfusion of drugs in the following order: morphine (1 μM), naloxone (1 μM), noradrenaline (3 μM), a saturating concentration of UK 14304 (3 μM), and idazoxan (1 μM). Noradrenaline perfusion included cocaine (3 μM) and the α1-adrenergic antagonist prazosin (100 nM). The NA-mediated current was compared to the current induced by UK 14304 (B) or morphine (C). Each data point represents an individual experiment. Line and error represents mean ± SEM. B, When compared to UK, the current produced by NA was not different in slices from naïve or morphine-treated rats indicating a lack of heterologous desensitization (p = 0.16, unpaired t-test). C, When compared to morphine, the NA-mediated current was larger in slices from morphine-treated rats (p = 0.03, unpaired t-test), which is due to reduction of the morphine-mediated current.

Figure 3. Recovery from morphine desensitization is facilitated by PP1.
Slices from morphine-treated rats were maintained in morphine (1 μM), then washed in morphine-free ACSF without (A) or with phosphatase inhibitors okadaic acid (100 nM) (B) or calyculin A (30 nM) (C) for various times (15 – 90 min) to monitor recovery from desensitization. Recordings were initiated in the absence of morphine. Morphine (1 μM) perfusion caused an outward current (I – morphine) that was normalized to UK 14304 (3 μM)-mediated current. In slices washed without phosphatase inhibitors (control; A), morphine (1 μM)-mediated current recovered from desensitization with a half-time of 44 ± 7 min (n = 3 – 6 per time point). When okadaic acid (B) was included in the morphine-free wash there was no effect on recovery (two-way ANOVA [F(1, 54) = 0.94, p = 0.34]; n = 3 – 8 per time point). In contrast, calyculin A (C) significantly delayed recovery from desensitization (two-way ANOVA [F(1, 39) = 5.8, p = 0.02]; n = 3 – 6 per time point).

Figure 4. Morphine washed out of slices in 20 min.

A, Recording in a slice from a naïve rat. Bath perfusion of morphine (1 μM) (shaded region) caused an outward change in the holding current (I - hold) and simultaneously reduced the current induced by iontophoretic application of ME (ME ionto, inset). B, Summary of the holding current (I - hold) at 2 min intervals (measured just before ME iontophoresis) during the wash in and out of morphine (1 μM); normalized to the maximum increase in holding current produced by morphine (1 μM) (n = 9). C, Summary of the amplitude of the ME current (as a percentage of the average amplitude of the first 3 ME currents) with (filled circles; n = 9) or without (open circles; n = 4) perfusion of morphine (1 μM).
Figure 5. Recovery from acute ME desensitization is facilitated by PP1.

Slices from naïve rats were used for acute ME-induced desensitization experiments. A, Example recording in an untreated slice from a naïve rat. An EC50 concentration of ME (0.3 μM) was perfused initially. Desensitization was induced using a saturating concentration of ME (30 μM) for 10 min. ME (0.3 μM) was perfused every 10 min to monitor recovery from desensitization. The amplitude of the ME (0.3 μM) test pulse was compared to the initial ME (0.3 μM) prepulse and plotted as % of prepulse in the summary graph (B). Treatment with of slices with calyculin A (30 nM) significantly delayed recovery from acute ME desensitization (two-way ANOVA \[F(2,46) = 7.08, p = 0.002\]; n = 8 – 9). *p < 0.05 by Bonferroni’s post-test

Figure 6. PKC (not JNK) inhibitors reverse morphine desensitization, but not tolerance.

A, Slices from naïve rats (open bars) were incubated without (Ctrl) or with inhibitors of JNK [SP600125 (10 μM, SP)] or PKC [Go6976 (1 μM, Go) or staurosporine (1 μM, Sts)] for 30 – 90 min. Inhibitors had no effect on morphine-mediated current in slices from naïve rats (p > 0.05 vs Naïve/Ctrl; n = 7 - 16). Slices from morphine-treated rats were maintained in morphine (1 μM) (MTA, morphine; filled bars) and kinase inhibitor (same as above) was added with morphine for 30 – 90 minutes before recording morphine current. The JNK inhibitor SP600125 did not change morphine desensitization (p > 0.05 vs MTA, morphine/Ctrl; n = 15). The PKC inhibitors Go6976 and staurosporine reversed
desensitization to a level similar to tolerant slices (p > 0.05 vs MTA, wash/Ctrl; n = 11). Some slices from morphine-treated rats were washed (MTA, wash; striped bars) and the PKC inhibitor Go6976 or the JNK inhibitor SP600125 was added to the wash for 1 – 4.5 h. Neither inhibitor changed long-lasting cellular tolerance (p > 0.05 vs MTA, wash/Ctrl; n = 8). All statistical comparisons were by one-way ANOVA and Bonferroni’s post-test. **p < 0.01, ***p < 0.001 compared to MTA, morphine/Ctrl. B, Slices from naïve rats were incubated in morphine (1 μM) for several hours with or without the JNK inhibitor SP600125. The negative slope of linear regression indicates gradual development of desensitization in control slices (slope = -3.5 ± 0.8 % of UK/ h, significantly non-zero p < 0.0001) and in slices with SP600125 added (slope = -3.8 ± 1.1 % of UK/ h, significantly non-zero p = 0.002). Thus, there was no effect of JNK inhibitor on the development of desensitization in slices from naïve rats (two-way ANOVA [F(1,41) = 2.1, p = 0.15]). Each data point represents an individual experiment.
Figure 2

A morphine (1 μM) NLX NA (3 μM) UK ida

B 100

C 200

I - NA (% of UK)

I - NA (% of morphine)

Naive MTA morphine

Naive MTA morphine

*
Figure 3
Figure 5

A

<table>
<thead>
<tr>
<th>ME (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3</td>
</tr>
<tr>
<td>30</td>
</tr>
<tr>
<td>0.3</td>
</tr>
<tr>
<td>0.3</td>
</tr>
<tr>
<td>0.3</td>
</tr>
<tr>
<td>0.3</td>
</tr>
<tr>
<td>UK_{ida}</td>
</tr>
</tbody>
</table>

B

Plot of I - ME (% of prepulse) vs. Recovery Time (min)

- Control
- Calyculin

* denotes significant difference at the *0.05 level.